Fondaparinux sodium injection
Formulation (FDF) · injection · 10mg/0.8ml； 7.5mg/0.6ml； 5mg/0.4ml； 2.5mg/0.5ml；
Formulation (FDF)Confidentiality：Public
- INN / Generic Name
- Fondaparinux sodium injection
- Dosage Form
- injection
- Strength
- 10mg/0.8ml； 7.5mg/0.6ml； 5mg/0.4ml； 2.5mg/0.5ml；
- Therapy Area
- Cardiovascular
- Indication
- Prevention of VTE in major lower limb orthopedic surgery; Treatment of deep vein thrombosis or pulmonary embolism; Treatment of unstable angina or NSTEMI not undergoing early PCI; Treatment of ST‑elevation MI undergoing thrombolysis or without initial reperfusion; Prophylaxis of VTE in acutely ill medical patients with reduced mobility
- Current Status
- Official FDF licensing catalog (UB835)
- GMP Certification
- US - FDA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- Registered (market rights transferable / DCP·NP per market)
- MOQ
- On request
- Lead Time
- On request
- Price Range
- On request
HS Code
3004.903 customs bills on file
Registrable Markets
United States
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price